Keros Therapeutics (KROS) Tops Q4 EPS by 22c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.14), $0.22 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $3.04 million versus the consensus estimate of $49.2 thousand.
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Coty (COTY) Misses Q4 EPS by 1c, offers outlook
- JPMorgan Reiterates Overweight Rating on Marvell (MRVL)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
